Citations

Mayo Clinic

Clear

5484 citation(s) found for "Wu, Stephen".

Utilisation of Acupuncture at An Academic Medical Centre
Vincent, Ann , Kruk, Kelly M., Cha, Stephen S, Bauer, Brent A. , Martin, David P. , Cha, Stephen S

Acupuncture in Medicine | September 22, 2010 | Volume: 28 | Issue: 4 | Pages: 189-190

10.1136/aim.2010.002568 | PMID 20861401 Get It

Objective To provide information about the clinical use of acupuncture at an academic medical centre in the USA. Methods A retrospective review of 904 patients (receiving 6070 treatments) who were referred for acupuncture treatment at the Mayo Clinic (Rochester, Minnesota, USA) between 1 January 2004 and 31 December 2008. Data gathered included age, sex, primary diagnosis, number of treatments per diagnosis and health insurance carrier. Results The mean (SD) age of the patients was 53.4 (16.2) years; 73.8% were female and 26.2% were male. The three most common diagnostic categories for which acupuncture was used were spinal pain (33.4%), pain (other) (25.1%) and joint pain (12.3%). About 42% of visits were not covered by health insurance carriers and hence patients had to pay themselves. For the remaining 58% of visits, health insurance carriers picked up all or part of the cost of the acupuncture treatments. Conclusion The results indicate that pain is the most common reason for use of acupuncture in an academic medical centre and that women use acupuncture more than men. This is one of the few reports of clinical use of acupuncture at academic medical centres in the USA.
Strategic Plan for Lung Vascular Research: An NHLBI-ORDR Workshop Report
Erzurum, Serpil C. , Rounds, Sharon , Stevens, Troy , Aldred, Micheala A. , Aliotta, Jason M., Asosingh, Kewal, Balaban, Robert S. , Bauer, Natalie , Bhattacharya, Jahar , Bogaard, Harm Jan , Choudhary, Gaurav , Dorn, Gerald W., Dweik, Raed A. , Fagan, Karen, Fallon, Michael B. , Finkel, Toren , Geraci, Mark W. , Gladwin, Mark T. , Humbert, Marc , Kaminski, Naftali , McMurtry, Ivan F., Newman, John H. , Nicolls, Mark R. , Rabinovitch, Marlene , Shizuru, Judy, Oka, Masahiko, Polgàr, Péter , Rodman, David M., Schumacker, Paul T. , Stenmark, Kurt R. , Tuder, Rubin M. , Voelkel, Norbert F., Sullivan, Eugene J., Weinshilboum, Richard M. , Yöder, Mervin C. , Zhao, Yingming , Gail, Dorothy B., Moore, Timothy M. , Archer, Stephen L. , Hassoun, Paul M. , Kawut, Steven M. , Loscalzo, Joseph , McDonald, Donald M. , Weinshilboum, Richard M. , Kaminski, Naftali

American Journal of Respiratory and Critical Care Medicine | September 10, 2010 | Volume: 182 | Issue: 12 | Pages: 1554-1562

10.1164/rccm.201006-0869ws | PMID 20833821 Get It

Abstract The Division of Lung Diseases of the National Heart, Lung, and Blood Institute, with the Office of Rare Diseases Research, held a workshop to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translational research needs, and ultimately the care of patients with pulmonary vascular diseases. Multidisciplinary experts with diverse experience in laboratory, translational, and clinical studies identified seven priority areas and discussed limitations in our current knowledge, technologies, and approaches. The focus for future research efforts include the following: (1) better characterizing vascular genotype–phenotype relationships and incorporating systems biology approaches when appropriate; (2) advancing our understanding of pulmonary vascular metabolic regulatory signaling in health and disease; (3) expanding our knowledge of the biologic relationships between the lung circulation and circulating elements, systemic vascular function, and right heart function and disease; (4) improving translational research for identifying disease-modifying therapies for the pulmonary hypertensive diseases; (5) establishing an appropriate and effective platform for advancing translational findings into clinical studies testing; and (6) developing the specific technologies and tools that will be enabling for these goals, such as question-guided imaging techniques and lung vascular investigator training programs. Recommendations from this workshop will be used within the Lung Vascular Biology and Disease Extramural Research Program for planning and strategic implementation purposes.
Albuminuria and the risk of incident stroke and stroke types in older adults
Aguilar, M.I., O’Meara, Ellen S. , Longstreth, W.T. , Hart, R. G., Katz, Ronit , Sarnak, Mark J. , Rifkin, Dena E. , Seliger, Stephen L. , Pérgola, Pablo E. , Shlipak, Michael G.

Neurology | September 2, 2010 | Volume: 75 | Issue: 15 | Pages: 1343-1350

10.1212/wnl.0b013e3181f73638 | PMID 20810996 Get It

Moesin1 and Ve-cadherin are required in endothelial cells during in vivo tubulogenesis
Kaiser, Mark S., Nasevicius, Aidas, Clark, Karl J. , Wadman, Shannon A., Roberg-Perez, Sharon E., Ekker, Stephen C. , Hackett, Perry B., McGrail, Maura , Essner, Jeffrey J. , Wang, Ying , Larson, Jon D. , Ekker, Stephen C , Clark, Karl J , McGrail, Maura , Essner, Jeffrey

Development | August 24, 2010 | Volume: 137 | Issue: 18 | Pages: 3119-3128

10.1242/dev.048785 | PMID 20736288 Get It

Endothelial tubulogenesis is a crucial step in the formation of functional blood vessels during angiogenesis and vasculogenesis. Here, we use in vivo imaging of living zebrafish embryos expressing fluorescent fusion proteins of β-Actin, α-Catenin, and the ERM family member Moesin1 (Moesin a), to define a novel cord hollowing process that occurs during the initial stages of tubulogenesis in intersegmental vessels (ISVs) in the embryo. We show that the primary lumen elongates along cell junctions between at least two endothelial cells during embryonic angiogenesis. Moesin1-EGFP is enriched around structures that resemble intracellular vacuoles, which fuse with the luminal membrane during expansion of the primary lumen. Analysis of silent heart mutant embryos shows that initial lumen formation in the ISVs is not dependent on blood flow; however, stabilization of a newly formed lumen is dependent upon blood flow. Zebrafish moesin1 knockdown and cell transplantation experiments demonstrate that Moesin1 is required in the endothelial cells of the ISVs for in vivo lumen formation. Our analyses suggest that Moesin1 contributes to the maintenance of apical/basal cell polarity of the ISVs as defined by adherens junctions. Knockdown of the adherens junction protein Ve-cadherin disrupts formation of the apical membrane and lumen in a cell-autonomous manner. We suggest that Ve-cadherin and Moesin1 function to establish and maintain apical/basal polarity during multicellular lumen formation in the ISVs.
Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
Maurer, Matthew J. , Link, Brian K. , Ansell, Stephen M. , Micallef, Ivana N. , Kelly, Jennifer L., Macon, William R. , Nowakowski, Grzegorz S. , Inwards, David J. , Johnston, Patrick B. , Allmer, Cristine, Weiner, George J. , Cerhan, James R. , Drake, Matthew T. , Habermann, Thomas M. , Singh, Ravinder J. , Slager, Susan L. , Witzig, Thomas E. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Weiner, George

Journal of Clinical Oncology | August 17, 2010 | Volume: 28 | Issue: 27 | Pages: 4191-4198

10.1200/jco.2010.28.6674 | PMID 20713849 Get It

Purpose Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL). Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL. Patients and Methods We tested the hypothesis that circulating 25-hydroxyvitamin D [25(OH)D] levels are predictive of event-free survival (EFS) and overall survival (OS) in a prospective cohort of 983 newly diagnosed patients with NHL. 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were measured by liquid chromatography-tandem mass spectrometry. Results Mean age at diagnosis was 62 years (range, 19 to 94 years); 44% of patients had insufficient 25(OH)D levels (< 25 ng/mL) within 120 days of diagnosis. Median follow-up was 34.8 months; 404 events and 193 deaths (168 from lymphoma) occurred. After adjusting for known prognostic factors and treatment, 25(OH)D insufficient patients with diffuse large B-cell lymphoma (DLBCL) had inferior EFS (hazard ratio [HR], 1.41; 95% CI, 0.98 to 2.04) and OS (HR, 1.99; 95% CI, 1.27 to 3.13); 25(OH)D insufficient patients with T-cell lymphoma also had inferior EFS (HR, 1.94; 95% CI, 1.04 to 3.61) and OS (HR, 2.38; 95% CI, 1.04 to 5.41). There were no associations with EFS for the other NHL subtypes. Among patients with DLBCL and T-cell lymphoma, higher 1,25(OH)2D levels were associated with better EFS and OS, suggesting that any putative tumor 1-α-hydroxylase activity did not explain the 25(OH)D associations. Conclusion 25(OH)D insufficiency was associated with inferior EFS and OS in DLBCL and T-cell lymphoma. Whether normalizing vitamin D levels in these patients improves outcomes will require testing in future trials.
Mutations in the Stalk Region of the Measles Virus Hemagglutinin Inhibit Syncytium Formation but Not Virus Entry
Ennis, Matthew K., Hu, Chunling , Naik, Shruthi , Hallak, Louay K. , Peng, Kah Whye, Russell, Stephen J. , Dingli, David , Russell, Stephen J , Hu, Chunling , Dingli, David

Journal of Virology | August 12, 2010 | Volume: 84 | Issue: 20 | Pages: 10913-10917

10.1128/jvi.00789-10 | PMID 20702637 Get It

ABSTRACT Measles virus (MV) entry requires at least 2 viral proteins, the hemagglutinin (H) and fusion (F) proteins. We describe the rescue and characterization of a measles virus with a specific mutation in the stalk region of H (I98A) that is able to bind normally to cells but infects at a lower rate than the wild type due to a reduction in fusion triggering. The mutant H protein binds to F more avidly than the parent H protein does, and the corresponding virus is more sensitive to inhibition by fusion-inhibitory peptide. We show that after binding of MV to its receptor, H-F dissociation is required for productive infection.
Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis
Gu, Jian , Hawk, Ernest T. , Ye, Yuanqing , Lee, Jeffrey H. , Hofstetter, Wayne L. , Wang, Kenneth K. , Wu, Xifeng , Ajani, Jaffer A. , Bhutani, Manoop S. , Swisher, Stephen G. , Gu, Jian

Cancer Prevention Research | July 22, 2010 | Volume: 3 | Issue: 9 | Pages: 1176-1186

10.1158/1940-6207.capr-09-0265 | PMID 20651033 Get It

Abstract To better understand the molecular mechanisms behind esophageal adenocarcinoma (EAC) tumorigenesis, we used high-density single nucleotide polymorphism arrays to profile chromosomal aberrations at each of the four sequential progression stages, Barrett's metaplasia (BM), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC, in 101 patients. We observed a significant trend toward increasing loss of chromosomes with higher progression stage. For BM, LGD, HGD, and EAC, respectively, the average numbers of chromosome arms with loss per sample were 0.30, 3.21, 7.70, and 11.90 (P for trend = 4.82 × 10−7), and the mean percentages of single nucleotide polymorphisms with allele loss were 0.1%, 1.8%, 6.6%, and 17.2% (P for trend = 2.64 × 10−6). In LGD, loss of 3p14.2 (68.4%) and 16q23.1 (47.4%) was limited to narrow regions within the FHIT (3p14.2) and WWOX (16q23.1) genes, whereas loss of 9p21 (68.4%) occurred in larger regions. A significant increase in the loss of other chromosomal regions was seen in HGD and EAC. Loss of 17p (47.6%) was one of the most frequent events in EAC. Many recurrent small regions of chromosomal loss disrupted single genes, including FHIT, WWOX, RUNX1, KIF26B, MGC48628, PDE4D, C20orf133, GMDS, DMD, and PARK2, most of which are common fragile site regions in the human genome. However, RUNX1 at 21q22 seemed to be a potential tumor suppressor gene in EAC. Amplifications were less frequent than losses and mostly occurred in EAC. 8q24 (containing Myc) and 8p23.1 (containing CTSB) were the two most frequently amplified regions. In addition, a significant trend toward increasing amplification was associated with higher progression stage. Cancer Prev Res; 3(9); 1176–86. ©2010 AACR.
Sodium Iodide Symporter (NIS)-Mediated Radiovirotherapy for Pancreatic Cancer
Penheiter, Alan R. , Wegman, Troy R., Classic, Kelly, Dingli, David , Bender, Claire E., Russell, Stephen J. , Carlson, Stephanie K., Russell, Stephen J , Dingli, David

American Journal of Roentgenology | July 22, 2010 | Volume: 195 | Issue: 2 | Pages: 341-349

10.2214/ajr.09.3672 | PMID 20651188 Get It

Iodixanol Versus Low-Osmolar Contrast Media for Prevention of Contrast Induced Nephropathy
From, Aaron M., Badarin, Firas Al , McDonald, Furman S., Bartholmai, Brian J. , Cha, Stephen S., Rihal, Charanjit S. , Cha, Stephen S., Rihal, Charanjit S. , Bartholmai, Brian J

Circulation: Cardiovascular Interventions | July 21, 2010 | Volume: 3 | Issue: 4 | Pages: 351-358

10.1161/circinterventions.109.917070 | PMID 20647563 Get It

Background— Contrast-induced nephropathy (CIN) is associated with significant morbidity and mortality. The objective of our meta-analysis was to assess the efficacy of iodixanol compared with low-osmolar contrast media (LOCM) for prevention of CIN. Methods and Results— We searched MEDLINE, the Cochrane Central Register of Controlled Trials, and internet sources of cardiology trial results for individual and relevant reviews of randomized, controlled trials, for the terms contrast media, contrast nephropathy, renal failure, iodixanol, Visipaque, and low-osmolar contrast media. All studies reported an incidence rate of CIN for each study group; there was no restriction on the definition of CIN. There were no restrictions on journal type or patient population. Overall, 36 trials were identified for analysis of aggregated summary data on 7166 patients; 3672 patients received iodixanol and 3494 patients received LOCM. Overall, iodixanol showed no statistically significant reduction in CIN incidence below that observed with heterogeneous comparator agents ( P =0.11). Analysis of patient subgroups revealed that there was a significant benefit of iodixanol when compared with iohexol alone (odds ratio, 0.25; 95% confidence interval, 0.11 to 0.55; P <0.001) but not when compared with LOCM other than iohexol or with other ionic dimers or among patients receiving intra-arterial contrast injections or among patients undergoing coronary angiography with or without percutaneous intervention. Conclusions— Analysis of aggregated summary data from multiple randomized, controlled trials of iodixanol against diverse LOCMs for heterogeneous procedures and definitions of CIN show an iodixanol-associated reduction that is suggestive but statistically nonsignificant.